For patients whove tried a GLP-1 and couldnt tolerate it, or who dont have access to one due to cost or insurance denial, Contrave is often the next logical option on the list, not a last resort
Wegovy does not have this specific approval
Moreover, the small number of trials and the potential presence of confounding factors further complicate the interpretation of these results
The strength of evidence for critical and essential outcomes was rated based on study design, risk of bias, consistency, limitations, directness, reporting precision and publication bias (Balshem et al
Dosing For most patients, dosing begins with the 0.25 mg pen for weekly injections for the first four weeks and increases to 0.5 mg on the fifth week of treatment
If you have kidney or heart limits, ask your clinician first